Trial Profile
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2016
Price :
$35
*
At a glance
- Drugs Dextromethorphan/quinidine (Primary)
- Indications Emotional lability
- Focus Therapeutic Use
- Sponsors Avanir Pharmaceuticals
- 18 Sep 2014 New trial record